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Hantaan virus (HTNV) causes hemorrhagic fever with renal syndrome (HFRS). Previous 
studies have identified interferon-induced transmembrane proteins (IFITMs) as an 
 interferon-stimulated gene family. However, the role of IFITMs in HTNV infection is 
unclear. In this study, we observed that IFITM3 single nucleotide polymorphisms (SNP) 
rs12252 C allele and CC genotype associated with the disease severity and HTNV 
load in the plasma of HFRS patients. In vitro experiments showed that the truncated 
protein produced by the rs12252 C allele exhibited an impaired anti-HTNV activity. We 
also proved that IFITM3 was able to inhibit HTNV infection in both HUVEC and A549 
cells by overexpression and RNAi assays, likely via a mechanism of inhibiting virus entry 
demonstrated by binding and entry assay. Localization of IFITM3 in late endosomes was 
also observed. In addition, we demonstrated that the transcription of IFITM3 is negatively 
regulated by an lncRNA negative regulator of interferon response (NRIR). Taken together, 
we conclude that IFITM3, negatively regulated by NRIR, inhibits HTNV infection, and its 
SNP rs12252 correlates with the plasma HTNV load and the disease severity of patients 
with HFRS.
Keywords: hantaan virus, hemorrhagic fever with renal syndrome, interferon-induced transmembrane protein 3, 
single nucleotide polymorphisms, negative regulator of interferon response
inTrODUcTiOn
Hantaan virus (HTNV), the prototype of Hantavirus and harbored mainly by Apodemus, is a patho-
gen that causes hemorrhagic fever with renal syndrome (HFRS) worldwide. Approximately, 150,000 
cases of HFRS are reported annually (1). The major clinical characteristics of patients with HFRS 
include fever, hemorrhage, hypotension, and renal injury (1). China is one of the most severely 
affected endemic countries of HFRS in the world, with a higher morbidity and mortality rate and more 
severe manifestations. It has been reported that the plasma HTNV load in the early stage of HFRS 
Table 1 | clinical and laboratory characteristics of the study population.
Mild patients severe patients P-value
Age (years) 45.21 ± 2.87 45.02 ± 2.27 0.9584
Gender (female/male) 6/22 6/35 0.5274
WBC (×109) 16.81 ± 1.82 22.26 ± 1.65 0.0326*
MONO % 12.92 ± 0.97 10.20 ± 0.65 0.0188*
Heteromorphic 
lymphocytes %
11.32 ± 1.47 10.93 ± 1.42 0.8568
PLT (×109) 64.75 ± 10.59 36.88 ± 5.63 0.0143*
BUN, mmol/l 14.84 ± 1.39 22.69 ± 1.50 0.0005**
Scr, μmol/l 241.30 ± 25.22 407.40 ± 34.14 0.0006**
WBC, white blood cells; PLT, platelets; MONO %, monocyte percentage; BUN, blood 
urea nitrogen; Scr, serum creatinine.
Values are presented as mean ± SEM.
P-value refers to the difference between mild and severe patients calculated by 
unpaired t-test. *P < 0.05, **P < 0.01 compared with mild patients.
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associates with the severity of disease, indicating the importance 
of viremia in the pathogenesis of HFRS (2). Therefore, further 
studies of host factors limiting HTNV infection and influencing 
antiviral response as well as disease progression are clinically 
significant and timely.
The human family of interferon-induced transmembrane 
proteins (IFITMs) was discovered 25  years ago to consist of 
interferon-stimulated genes (ISGs) (3). This family includes five 
members, namely, IFITM1, 2, 3, 5, and 10, among which IFITM1, 
2, and 3 possess antiviral activity (4). Different IFITM proteins 
have different antiviral spectrum (5). For example, IFITM3 has 
been shown to prevent influenza virus infection in vitro and in 
mice (6, 7), and it also inhibits multiple viruses, including filovi-
ruses, rhabdoviruses, flaviviruses, and even Ebola and Zika virus 
(7–11). The antiviral mechanism of IFITM3 is thought to be the 
restriction of viral entry into cells (4, 12). Single nucleotide poly-
morphisms (SNPs) are single nucleotide variations in a genetic 
sequence that occur at an appreciable frequency in the popula-
tion. Several SNPs has been identified in IFITM3, among which 
the rs12252 site with C allele results in a N-terminal truncation of 
IFITM3 protein, leading to impaired inhibition of influenza virus 
in vitro (13, 14). Notably, the frequencies of rs12252 C allele and 
CC genotype correlate with disease severity in patients infected 
with influenza virus (13, 15). HTNV has been shown to induce 
a type I interferon response (though in later time postinfection) 
(16, 17). While overexpression of IFITM1, 2, and 3 in Vero E6 
cells has been reported to inhibit HTNV infection (18), however, 
the effect of IFITMs on HTNV infection in human cell lines and 
its role in HFRS still remain unknown.
LncRNA comprises a group of non-coding RNAs longer than 
200 nt that function as gene regulators. Some lncRNAs have been 
shown to play a role in innate immunity (19). Among them, nega-
tive regulator of interferon response (NRIR) (lncRNA NRIR, also 
known as lncRNA-CMPK2) is a non-coding ISG that negatively 
regulates IFITM1 and Mx1 expression in HCV infection (20). 
Notably, IFITM3 is largely homologous to IFITM1, but the role 
of NRIR in the regulation of IFITM3 in HTNV infection remains 
unclear.
In the present study, we investigate the effect of IFTTM3 
on the replication of HTNV and its role in the development of 
HFRS in humans. We provide primary evidence suggesting that 
IFITM3, regulated by NRIR, can inhibit HTNV infection and its 
SNP rs12252 correlates with the disease severity and viral load in 
patients with HFRS. This study expands our understanding of the 
antiviral activity of IFITM3 and enriches our knowledge of innate 
immune responses to HTNV infection.
MaTerials anD MeThODs
ethics statement
This study was conducted in accordance with the recommenda-
tions of the biomedical research guidelines involving human par-
ticipants established by the National Health and Family Planning 
Commission of China. The Institutional Ethics Committee of 
Tangdu Hospital approved this study. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki. 
Before inclusion, all participants were informed of the study 
objectives and signed the consent form before blood samples and 
medical records were obtained.
study Participants
Sixty-nine HFRS patients admitted into the Department of 
Infectious Diseases, Tangdu Hospital between October 2014 
and March 2016 were enrolled in this study. All patients were 
Han Chinese. The diagnosis of HFRS was made based on typical 
symptoms and signs as well as positive IgM and IgG antibodies 
against HTNV in the serum assessed by enzyme linked immu-
nosorbent assay (ELISA) in our department. The classification 
of HFRS severity and the exclusion criteria were described as 
follows (21): white blood cells (WBC), platelets (PLT), blood 
urea nitrogen (BUN), serum creatinine (Scr), and heteromorphic 
lymphocytes that were tested by the Department of Clinical 
Laboratory (shown in Table 1).
According to clinical symptoms and signs, such as fever, 
effusion, hemorrhage, edema, and renal function, the sever-
ity of HFRS can be classified as previously described (21): (1) 
mild patients were identified with mild renal failure without an 
obvious oliguric stage; (2) moderate patients were those with 
obvious symptoms of uremia, effusion (bulbar conjunctiva), 
hemorrhage (skin and mucous membrane), and renal failure 
with a typical oliguric stage; (3) severe patients had severe 
uremia, effusion (bulbar conjunctiva and either peritoneum or 
pleura), hemorrhage (skin and mucous membrane), and renal 
failure with oliguria (urine output, 50–500 ml/day) for ≤5 days 
or anuria (urine output, <50 ml/day) for ≤2 days; and (4) critical 
patients exhibited ≥1 of the following signs during the illness: 
refractory shock, visceral hemorrhage, heart failure, pulmonary 
edema, brain edema, severe secondary infection, and severe renal 
failure with oliguria (urine output, 50–500 ml/day) for >5 days, 
anuria (urine output, <50 ml/day) for >2 days, or a BUN level 
of >42.84 mmol/l. Due to the sample quantity required for SNP 
typing, the mild and moderate patients were assessed together in 
the mild group, and we combined severe and critical patients as 
severe group.
The exclusion criteria for this study were patients with: (1) 
any other kidney disease, (2) diabetes mellitus, (3) autoimmune 
disease, (4) hematological disease, (5) cardiovascular disease, 
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(6) viral hepatitis (types A, B, C, D, or E), or (7) any other liver 
disease. In addition, no patients received corticosteroids or other 
immunomodulatory drugs during the study period (21).
sequencing and genotyping of snPs
Genomic DNA was extracted from the peripheral blood of 
patients using the PureGene DNA Isolation kit (Gentra Systems, 
Minneapolis, MN, USA). The region encompassing the human 
IFITM3 rs12252 were amplified by PCR (forward primer, 
5′-GGAAACTGTTGAGAAACCGAA-3′ and reverse primer, 
5′-CATACGCACCTTCACGGAGT-3′). The PCR products were 
purified and sequenced using an Applied Biosystems 3730xl DNA 
Analyzer (Thermo Scientific, Waltham, MA, USA). The allele 
frequencies and genotypes of healthy Han Chinese and other 
groups were obtained from the 1,000 genomes project (http://
www.1000genomes.org).
Determination of the Plasma hTnV load
The HTNV load in plasma samples (collected during the acute 
phase) from 24 age- and sex-matched HFRS patients with 
different genotypes were measured using previously reported 
methods (2). Briefly, viral RNA was extracted from the plasma of 
HFRS patients using Purelink Viral RNA/DNA Kits (Invitrogen, 
Carlsbad, CA, USA). The SuperScript III Platinum One-Step 
Quantitative RT-PCR System kit (Invitrogen, Carlsbad, CA, 
USA) was employed for the real-time RT-PCR assay. The primers 
and probe (provided by Sangon Biotech, Shanghai, China) were 
as follows: forward, 5′-TACAGAGGGAAATCAATGCC-3′, 
reverse, 5′-TGTTCAACTCATCTGGATCCTT-3′, and probe, 
5′-(FAM) ATCCCTCACCTTCTGCCTGGCTATC (TAMRA)-
3′. The synthetic S segment of the HTNV standard strain 
76–118 RNA transcript was used as the quantitative calibrator. 
The external standard was the culture supernatant of Vero E6 
cells infected with HTNV 76–118, which was quantified using 
synthetic quantitative calibrators. For each experiment, one 
aliquot of calibrated 76–118 standard was extracted in paral-
lel with the clinical samples and serially 10-fold diluted with 
concentrations ranging from 10.56 to 2.56 log10 copies/ml. PCR 
was performed using an iQ5 Cycler (Bio-Rad, Hercules, CA, 
USA) with following conditions: 42°C for 15  min, 95°C for 
2 min, and 50 cycles of 15 s at 95°C, 30 s at 53°C, and 30 s at 
72°C. Fluorescence was read during the 72°C step of the final 
segment of every cycling program.
cells, Virus, and iFn-α2a
HUVEC cells (ScienCell Research Laboratories, Carlsbad, 
CA, USA) were grown in ECM BulletKit (ScienCell Research 
Laboratories, Carlsbad, CA, USA) in a 5% CO2 incubator. A549 
cells (ATCC Cat# CRM-CCL-185, RRID:CVCL_0023) were 
grown in our laboratory in DMEM with 10% FBS (Thermo 
Scientific, Waltham, MA, USA) in a 5% CO2 incubator. Cells 
were used within passage 10 after primary culture. HTNV strain 
76–118 was cultured in Vero E6 cells (ATCC Cat# CRL-1586, 
RRID:CVCL_0574) in our laboratory and titrated using an 
immunofluorescence staining assay for HTNV nucleocapsid 
protein (NP) as previously described (22). The TCID50 was 
105/ml, which was calculated using the Reed-Muench method. 
The recombinant human IFN-α2a was obtained from PBL 
Interferon Source (Piscataway, NJ, USA) and dissolved in the 
buffer provided by the manufacturer (composition not dis-
closed). HUVEC and A549 cells were infected by incubation 
with HTNV as indicated moi at 37°C for 60 mins. Subsequently, 
the virus solution was removed and fresh medium added to the 
cell culture.
expression and rnai of iFiTM Molecules
Cells were transfected with lentiviral vectors of c-myc-tagged 
IFITM1, IFITM2, IFITM3, and IFITM3 NΔ21 (purchased from 
GENECHEM, Shanghai, China) at a moi of 10. Puromycin (2 μg/
ml for HUVEC and 6 μg/ml for A549 cells) was used to create cell 
lines stably expressing IFITMs. Cells were transfected with con-
trol (scrambled) short interfering RNA (siRNA), IFITM1 siRNA, 
IFITM2 siRNA, or IFITM3 siRNA (10 nM) using Lipofectamine 
3000 transfection reagent (Invitrogen, Carlsbad, CA, USA). 
SiRNAs were purchased from Origene (Rockville, MD, USA), 
and the sequences were not disclosed.
Quantitative real-time Pcr analysis
Total RNA was extracted using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA), and cDNA was synthesized using the K1622 
kit (Thermo Scientific, Waltham, MA, USA). Quantitative real-
time PCR (qPCR) was performed using SYBR Premix Ex Taq II 
(Takara Biotechnology Co., Dalian, China) with a Bio-Rad iQ5 
cycler (Bio-Rad, Hercules, CA, USA). β-actin was used as the 
reference gene. The primers (Sangon Biotech, Shanghai, China) 
were as follows:
IFITM1 (forward, 5′-ACTCCGTGAAGTCTAGGGACA-3′ and 
reverse, 5′-TGTCACAGAGCCGAATACCAG-3′);
IFITM2 (forward, 5′-ATCCCGGTAACCCGATCAC-3′ and 
reverse, 5′-CTTCCTGTCCCTAGACTTCAC-3′);
IFITM3 (forward, 5′-GGTCTTCGCTGGACACCAT-3′ and 
reverse, 5′-TGTCCCTAGACTTCACGGAGTA-3′);
IFITM3 pre-mRNA (forward, 5′-CATAGCACGCGGCTCT 
CAG-3′ and reverse, 5′-CGTCGCCAACCATCTTCCTG-3′);
HTNV S segment (forward, 5′-GCCTGGAGACCATCTGA 
AAG-3′ and reverse, 5′-AGTATCGGGACGACAAAGGA-3′);
β-actin (forward, 5′-GCTACGTCGCCCTGGACTTC-3′ and 
reverse, 5′-GTCATAGTCCGCCTAGAAGC-3′);
NRIR (forward, 5′-ATGGTTTTCTGGTGCCTTG-3′ and 
reverse, 5′-GGAGGTTAGAGGTGTCTGCTG-3′);
NRAV (forward, 5′-TCACTACTGCCCCAGGATCA-3′ and 
reverse, 5′-GGTGGTCACAGGACTCATGG-3′).
For detection of miR-130a, cDNA was synthesized using 
the TaqMan microRNA reverse transcription kit (Invitrogen, 
Carlsbad, CA, USA) with a specific primer in gene-specific 
TaqMan assay kit (000454, Invitrogen, Carlsbad, CA, USA). 
MiR-130a level was determined using the gene-specific TaqMan 
assay kit (000454, Invitrogen, Carlsbad, CA, USA). U6 (001973, 
Invitrogen, Carlsbad, CA, USA) was used as an endogenous 
control (23). Because the pre-mRNA levels can represent the 
initial transcription rate (24), the primers used to detect the 
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pre-mRNA of IFITM3 were designed targeting the intron of 
IFITM3 as previously described (25). IFITM3 has two exons 
and one intron. For qPCR of IFITM3 pre-mRNA, the forward 
primers were positioned in the intron, and the reverse primer 
was positioned at the beginning of the second exon. For qPCR of 
IFITM3 mRNA, the forward primers were positioned in the first 
exon, and the reverse primer was positioned at the beginning of 
the second exon (24). Because the basal expression of IFITM3 is 
low in A549 cells, we detected IFITM3 mRNA and pre-mRNA 
in A549 cells following IFN-α2a treatment (20 IU/ml for 12 h) 
after the overexpression of NRIR.
Western blot analysis
Cell lysates were prepared using Radio Immunoprecipitation 
Assay (RIPA) buffer (Sigma-Aldrich, St. Louis, MO, USA). Equal 
amounts of protein (20 μg protein/lane) were electrophoresed on a 
10%-SDS-polyacrylamide gel and electrophoretically transferred 
to a polyvinylidene difluoride membrane (Millipore, Billerica, 
MA, USA). After blocking with 5% bovine serum albumin in Tris-
buffered saline at room temperature for 1 h, the membranes were 
incubated with antibodies against IFITM1 (Proteintech Group 
Cat# 60074-1-Ig Lot# RRID:AB_2233405), IFITM2, IFITM3 
(Proteintech Group Cat# 66081-1-Ig Lot# RRID:AB_11182821), 
and β-actin (Proteintech, Wuhan, Hubei, China) or HTNV 
NP (provided by the Department of Microbiology, The Fourth 
Military Medical University) overnight at 4°C. The membranes 
were then washed and incubated with HRP-conjugated IgG anti-
body (Cell Signaling Technology, Danvers, MA, USA) for 1 h at 
room temperature. The blots were developed using an enhanced 
chemiluminescence detection kit (Millipore, Billerica, MA, USA) 
and visualized using X-ray film. The blot densities were analyzed 
using the Quantity One software (Bio-Rad, Hercules, CA, USA). 
In addition, the RIPA buffer contains 50mM Tris (pH =  7.4), 
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% 
SDS. Protease inhibitor cocktail (Roche, Basel, Switzerland) was 
added before use.
immunofluorescence and confocal 
Microscopy
The cells were cultured on glass coverslips (Millipore, Billerica, 
MA, USA) until they were semi-confluence and then incubated 
with HTNV for 60 min (moi = 1). At the indicated times post-
HTNV infection, the cells were fixed with 4% PFA, incubated 
with 0.3% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA), 
and blocked with 5% BSA for 1 h. Following incubation with a 
mouse monoclonal antibody against c-myc-tag (Sigma-Aldrich, 
St. Louis, MO, USA, Sigma-Aldrich Cat# M5546), IFITM3, 
lysosome-associated membrane glycoprotein 1 (LAMP1, Cell 
Signaling Technology, Danvers, MA, USA), or HTNV NP at 37°C 
for 2 h, the cells were washed and incubated with anti-rabbit Ig 
conjugated to Alexa 555 and anti-mouse Ig conjugated to Alexa 
488 (Abcam, Cambridge, MA, USA) secondary antibodies at 
room temperature for 1 h. The nuclei were counterstained with 
DAPI. An Olympus BX51 fluorescence microscope system and 
FV1000 confocal microscopy system (Olympus, Tokyo, Japan) 
were used to capture the images.
hTnV binding and entry assay
Cells transduced with IFITM3 or the empty vector were detached 
and washed extensively with cold PBS. The cells and HTNV were 
pre-chilled on ice for 30 min, mixed at a moi of 1 and incubated at 
4°C for 1 h with rotation. Part of cells were washed extensively with 
ice-cold PBS and harvested for binding assay. Another part of cells 
were switched to 37°C for 2 h to allow HTNV entry. The HTNV 
that remained on the cell surface was removed by treatment with 
proteinase K (0.1 mg/ml, Thermo Scientific, Waltham, MA, USA). 
To achieve direct entry of HTNV into cells by virus–plasma mem-
brane fusion as a positive control, cells were pre-chilled on ice for 
10 min with 20 mM NH4Cl. Adsorption of HTNV (moi = 1) was 
performed at 4°C for 1 h. The cells were then washed, and fusion 
of the virus with the plasma membrane was triggered by incuba-
tion in low pH medium (20 mM sodium succinate, pH = 5.5) for 
10 min at 37°C. Infection was followed by incubation for 2 h at 
37°C in the presence of 20  mM NH4Cl (26). qPCR analysis of 
the HTNV S segment was conducted to evaluate the influence of 
IFITMs on HTNV cell adhesion and HTNV entry.
statistical analysis
All data were expressed as the mean ± SEM. Statistical analyses 
were performed using GraphPad Prism 5 (GraphPad Software, 
La Jolla, CA, USA). For association analysis of the rs12252 
allele and genotype, Fisher’s exact test was used. Independent 
samples t-tests were used for normally distributed data. 
Differences among groups were determined by one-way analysis 
of variance (ANOVA) with repeated measures, followed by 
Bonferroni’s post hoc test. P <  0.05 was considered statistically 
significant.
resUlTs
The iFiTM3 snP rs12252 c allele and cc 
genotype associated with severe hFrs 
Disease and a higher Plasma hTnV load
To determine the clinical significance of IFITM3 SNP in HTNV 
infection, the relationship between rs12252 SNP and the severity 
of HFRS in 69 patients were examined. We sequenced 300  bp 
of the IFITM3 locus encompassing SNP rs12252 in all enrolled 
patients. Then, we stratified these patients into mild and severe, 
based on the clinical assessment as described in Section “Material 
and Methods.” We found a significantly higher frequency of the 
C allele among severe HFRS patients compared with the healthy 
Han Chinese in the 1,000 genomes sequence database (68.29 
vs. 52.16%, P = 0.0076). The frequency of rs12252 C in severe 
patients was also higher than those mild patients (68.29 vs. 
46.43%, P = 0.013, Figures 1A,B; Table 2). These data suggest 
that harboring rs12252 C allele increases the risk of suffering 
severe disease in HTNV-infected individuals, with an odds ratio 
(95% CI) of 2.124 (1.067–4.230). For genotypes, 43.90% of the 
severe patients carried the CC genotype, a significantly higher 
frequency than the control Han Chinese per 1,000 genomes 
sequence database (26.92% CC genotype, P  =  0.03) as well 
as mildly infected patients (14.29%, P =  0.02, Figures  1A,B; 
Table  2). However, mildly ill individuals did not exhibit a 
FigUre 1 | association of iFiTM3 snP rs12252c allele and cc genotype with the disease severity and plasma hTnV load in hFrs patients. (a) SNP 
analysis of rs12252 allele and genotype frequencies between severe HFRS patients and healthy Han Chinese. (b) SNP analysis of rs12252 allele and genotype 
frequencies between severe HFRS patients and mild HFRS patients. Fisher’s exact test was used to test the association between rs12252 allele/genotype and 
HFRS severity. (c) The plasma HTNV load in CC genotype patients and CT/TT genotype patients, tested by qRCR analysis. Each symbol represents one individual 
patient. Independent samples t-test was used to test the difference of HTNV load between groups. *P < 0.05, **P < 0.01.
Table 2 | allele and genotype frequencies of iFiTM3 snP rs12252 in chinese hFrs patients and different healthy subjects from the 1,000 genome 
project.
genotypes from the 1,000 genomes project hFrs patients from our hospital
northern europe european 
american
han chinese all hospitalized Mild patients severe patients
genotype
CC 0 (0%) 5 (0.12%) 56 (26.92%) 22 (31.88%) 4 (14.29%) 18 (43.90%)
CT 7 (8.05%) 323 (7.79%) 105 (50.48%) 38 (55.07%) 18 (64.29%) 20 (48.78%)
TT 80 (91.95%) 3816 (92.08%) 47 (22.60%) 9 (13.04%) 6 (21.43%) 3 (7.32%)
Allele C 7 (4.02%) 333 (4.02%) 217 (52.16%) 82 (59.42%) 26 (46.43%) 56 (68.29%)
Allele T 167 (95.98%) 7955 (95.98%) 199 (47.84%) 56 (40.58%) 30 (53.57%) 26 (31.71%)
statistical analysis*
Genotype
P-value 0.44 0.17 0.03*
Odds ratio (95% CI) 1.271 (0.7029–2.296) 0.4524 (0.1503–1.362) 2.124 (1.067–4.230)
HWE P-value 0.24 0.12 0.42
Allele
P-value 0.14 0.48 0.0076*
Odds ratio (95% CI) 1.343 (0.9087–1.984) 0.7948 (0.4542–1.391) 1.975 (1.194–3.268)
The Hardy–Weinberg equilibrium (HWE) test was conducted in each patient group. Fisher’s exact test was used for association testing of the rs12252 allele and genotype. *P < 0.05 
compared with the Han Chinese. The bold font highlights significant difference.
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significantly different genotype frequencies compared with the 
Han Chinese population. In addition, we also found that patients 
with CC genotype had higher plasma viral load in acute phase 
(Figure  1C). These results support the notion that the normal 
function of IFITM3 plays a critical role in the immune response 
to HTNV infection in  vivo, which has a substantial influence 
on the clinical manifestation of HFRS.
iFiTM3 snP rs12252 Polymorphisms 
influenced its anti-hTnV activity
Previous studies reveal that the truncated IFITM3 protein 
produced by SNP rs12252 C allele (Figure 2A, the missing part 
stands for the truncated 21 amino acids from N-terminal of 
IFITM3, the intramembrane helix, and transmembrane helix 
was presented as boxes) leads to an impaired anti-influenza 
FigUre 2 | The iFiTM3 snP rs12252 polymorphism influenced its anti-hTnV activity. (a) The molecular dissection of IFITM3 protein and the location of 
SNP rs12252 (close to N-terminal showed by red arrow) which encodes a splice acceptor site altering T/C substitution mutation, resulting in a truncated protein 
with an N-terminal 21 amino acid deletion. The absence of the first N-terminal 21 amino acids was showed as red dotted line (deleted part). The C-terminal 
transmembrane α-helix and an N-terminal intramembrane segment was showed as black boxes. (b) HUVEC and A549 cells transduced to express either 
full-length (IFITM3) or truncated (NΔ21) IFITM3. c-myc-tag was stained red. (c,D) The expression of HTNV S segment in HUVEC and A549 cells transfected with 
empty vector (NC), full-length IFITM3, or truncated IFITM3 (NΔ21), determined by qPCR, n = 8. Data are presented as mean ± SEM. **P < 0.01 vs. NC, 
##P < 0.01 vs. IFITM3.
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activity (14). To test the functional significance of this poly-
morphism in HTNV infection, we transfected the majority T 
or minority C variant IFITM3 alleles that produce full-length 
or N-terminally truncated (NΔ21) proteins (Figure 2A) with 
c-myc-tag to HUVEC and A549 cell using lentivirus vec-
tors (Figure  2B). Then, we challenged the cells with HTNV 
at moi = 1 for 24 h and found that cells with the minority C 
variant were more susceptible to HTNV infection with higher 
expression of HTNV S segment (Figure 2C) and more positive 
of HTNV NP (Figure S3 in Supplementary Material). Indeed, 
compared with the mock (empty vector)-infected control, the 
NΔ21 protein almost lost the ability to inhibit HTNV infection 
in both HUVEC and A549 cells (Figures  2C,D; Figure S3 in 
Supplementary Material).
hTnV infection induced the expression 
of iFiTMs
To determine the role of HTNV infection in inducing IFITMs, 
qPCR as well as Western blot of IFITMs were conducted in HUVEC 
and A549 cells (Figures  3A,B; Figure S1 in Supplementary 
Material). While we observed only a moderate upregulation of 
IFITM1, 2, and 3 mRNA and protein in HUVECs after more than 
24 h postinfection; IFITM1, 2, and 3 mRNA, however, were only 
transiently upregulated in A549 cells and caused no significant 
change in protein level.
endogenous iFiTM3 contributed 
significantly to the anti-hTnV effect 
of iFn-α2a
We knocked down the IFITM1, 2, and 3 expression by transfec-
tion of their siRNAs individually. The effect of siRNAs on the 
expression of target IFITMs was tested by qPCR in HUVECs 
(Figure S2 in Supplementary Material), and the effect of the best 
oligo against each IFITMs (IFITM1C, IFITM2A, IFITM3B) was 
tested by Western blot in A549 (Figure 4A) and HUVEC cells 
(Figure 4B). To assess the role of IFITMs in anti-HTNV effect 
of IFN-α2a, IFITM1, 2, and 3 were knocked down respectively 
by transfecting the above-tested oligoes for 12  h, followed by 
IFN-α2a treatment (20 IU/ml for another 12 h). The cells were 
then challenged with HTNV (moi =  1) for 24  h. The HTNV 
S segment and NP levels were significantly suppressed in both 
HUVEC and A549 cells in response to IFN-α2a treatment. 
Notably, knockdown of IFITM3 significantly restored the lev-
els of HTNV S segment and NP in HUVEC and A549 cells. 
Knockdown of IFITM1 also partially restored the HTNV level 
in A549 cells (Figures  4C,D). These results demonstrate that 
FigUre 3 | identification of iFiTM3 alteration after hTnV infection. (a) qPCR analysis of IFITM1, 2, and 3 in HUVEC and A549 cells infected by HTNV or 
Mock control (Con) at indicated time point post infection. (b) Western blot analysis of IFITM3 expression in HUVEC and A549 cells infected by HTNV or Mock 
control (Con) at indicated time point post infection. n = 8 for qPCR; n = 6 for Western blot analysis. Data are presented as mean ± SEM. Con: mock infection, 
12–72 h: time postinfection, IFN: A549 cells treated with IFN-α2a (20 U/ml) serves as a positive control. *P < 0.05, **P < 0.01 vs. Con.
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endogenous IFITM3 significantly contributed to the anti-HTNV 
effect of IFN-α2a.
Overexpression of iFiTM3 inhibited hTnV 
infection by Preventing cytoplasmic entry
To assess the anti-HTNV effects of IFITMs, we tested the 
effect of overexpressed IFITM1, 2, and 3 on HTNV infec-
tion. c-myc-tagged IFITM1, 2, and 3 were expressed in both 
HUVEC and A549 cells (Figure 5A), and the cells were then 
challenged with HTNV (moi = 1) for 24 h. The HTNV S seg-
ment and NP levels were suppressed by IFITM3 overexpression 
in HUVEC cells (Figures 5B–D). They were also suppressed by 
expressing IFITM1 and IFITM3 in A549 cells (Figures 5B–D). 
The inhibitory effect of IFITM3 was further confirmed by 
immunofluorescence analysis of HTNV NP (Figure S3 in 
Supplementary Material). These results were in accordance 
with the above-described RNAi results. To determine whether 
IFITM3 inhibited HTNV binding or entry, HUVEC and A549 
cells were incubated with HTNV (moi =  1) at 4°C for 1  h, 
unbound virus was washed away, and HTNV RNA collected 
at this time point represents HTNV bound to the cell surface. 
After virus binding, the cells were shifted to 37°C for 2 h to allow 
HTNV internalization, and HTNV RNA collected at this time 
point represents cell-internalized virus. As a positive control for 
inhibition of virus entry, we incubated a parallel group of cells 
with HTNV at pH = 5.5 as described in Section “Materials and 
Methods.” Expression of IFITM3 did not affect HTNV binding 
(Figure 6A) but significantly suppressed HTNV entry in both 
HUVEC and A549 cells (Figure 6B).
FigUre 4 | contribution of endogenous iFiTMs to the anti-hTnV effect of iFn-α2a. (a,b) Representative Western blot imaging for the effectiveness of the 
respective RNAi on IFITM1, 2, and 3 expression. A549 and HUVEC cells were transfected with indicated siRNAs for 12 h, treated with mock or IFN-α2a for 12 h, 
and then infected by HTNV (moi = 1) for another 24 h, followed by Western blot analysis, as described in Section “Materials and Methods.” (c,D) Effect of IFITM1, 
2, and 3 RNAi on HTNV infection in HUVEC and A549 cells. The cells were treated as described above, HTNV replication was evaluated by qPCR for HTNV S 
segment (n = 8) and Western blot for HTNV NP (n = 6). Data are presented as mean ± SEM. Control: mock-infected and non-targeting siRNA group, NC: 
non-targeting siRNA group, IFN + NC: control siRNA + IFN-α2a group, IFN + RNAi:siRNA of the indicated IFITM + IFN-α2a group. **P < 0.01 vs. control, #P < 0.05, 
##P < 0.01 vs. NC, &P < 0.05, &&P < 0.01, vs. NC + IFN.
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iFiTM3 Was Partially localized to laMP1+ 
late endosomes in the host cells
To elucidate the mechanism of IFITM3 function, we investigated 
the subcellular localization of IFTIM3 in the host cells. IFITM3 
was found partially localized to LAMP1+ late endosomes in 
HUVECs analyzed by confocal microscopy (Figure  6C). The 
co-localization of IFITM3 and LAMP1+ late endosomes had also 
been found in A549 cells (27). Because the transfer into LAMP1+ 
late endosomes is a necessary step for HTNV entry (28), this 
result provides an evidence for the anti-HTNV mechanism of 
IFITM3.
lncrna nrir negatively regulated 
the initial Transcription of iFiTM3 
and Facilitated hTnV infection
LncRNA- and microRNA-mediated regulation of IFITM3 has 
been reported in several studies. We tested the change of pre-
viously reported regulators of IFITMs, such as NRAV, NRIR, 
and miR-130a after HTNV infection, among which NRIR was 
the only changed one (downregulated) after HTNV infection 
(Figure 7A; Figure S4 in Supplementary Material) in HUVEC. 
However, the expression of NRIR was unchanged in A549 cells. 
We overexpressed NRIR in HUVEC and A549 cells using the 
pcDNA3.1 vector (Figure  7B). Importantly, overexpression of 
NRIR significantly suppressed IFITM3 mRNA and pre-mRNA 
levels and facilitated HTNV infection in HUVEC and A549 cells 
(Figures 7C–E). These data suggest that lncRNA NRIR is a nega-
tive regulator of IFITM3 transcription.
DiscUssiOn
Hantaan virus is an enveloped, negative-sense RNA virus from 
the genus Hantavirus within the family Bunyaviridae. It causes 
HFRS, which is an important threat to public health worldwide. 
It is also a potential weapon for biological terrorism. Reservoir 
animals, usually rodents, are asymptomatic during persistent 
infection. Unlike in rodents, Hantavirus infection leads to 
HFRS and Hantavirus pulmonary syndrome (HPS) in humans 
(21). The major clinical characteristics of HFRS include fever, 
hemorrhage, hypotension, and renal injury (1,  21), causing 
severe manifestations and death in some cases. The current 
FigUre 5 | inhibitory effect of overexpressed iFiTMs on hTnV infection. (a) Confirmation of c-myc-tagged IFITM1, 2, and 3 overexpression by lentiviral 
vector. c-myc-tag was stained red, nucleus was counterstained with DAPI. (b,c) Effect of IFITM1, 2, and 3 overexpression on HTNV infection in HUVEC and A549 
cells (moi = 1 for 24 h), assessed by qPCR for HTNV S segment. NC: control vector group, IFITM1-LV: IFITM1 overexpression group, IFITM2-LV: IFITM2 
overexpression group, IFITM3-LV: IFITM3 overexpression group. Data are presented as mean ± SEM. N = 8. **P < 0.01 vs. NC (D) Effect of IFITM1, 2, and 3 
overexpression on HTNV infection in HUVEC and A549 cells (moi = 1 for 24 h), tested by Western blot for HTNV NP. Data are presented as mean ± SEM. N = 6. 
**P < 0.01 vs. A549 NC in (D), ##P < 0.01 vs. HUVEC NC.
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standard of care for HFRS relies on symptomatic and support-
ive treatment. It has been confirmed that the plasma viral load 
is associated with the severity of HFRS, implicating the impor-
tance of viremia in the pathogenesis of HFRS (2). However, 
no direct antiviral medications are currently available for this 
illness. Interferon is the key molecule for the antiviral response 
and has been used as an antiviral medicine in many diseases. 
It has been reported that HTNV infection induces a late type 
I interferon response (16). However, the set of ISGs required 
for IFN-mediated inhibition of HTNV has not yet been identi-
fied. Therefore, identification of ISGs that are effective against 
HTNV is an attractive strategy to identify novel therapeutic 
targets.
In this study, we demonstrated a significantly high frequency 
of the rs12252 C allele and CC genotype among HFRS patients 
with severe illness compared with mildly infected individuals 
and the healthy Han Chinese. The rs12252 C allele and CC 
genotype are also found to be associated with higher plasma 
viral load in the early stage of HFRS. We also discovered that 
HTNV infection induces IFITMs, and the truncated IFITM3 
produced by rs12252 C allele exhibits significantly decreased 
anti-HTNV activity. Interestingly, IFITM3 is found to restrict 
FigUre 6 | iFiTM3 inhibits hTnV entry into hUVec and a549 cells and partially localizes to laMP1+ late endosomes. (a,b) The influence of IFITM3 on 
HTNV-HUVEC and HTNV-A549 cell binding and cellular entry. NC: control vector group, IFITM3-LV: IFITM3 overexpression group, AC: virus-plasma membrane 
fusion group, Data are presented as mean ± SEM, n = 8. *P < 0.05, **P < 0.01 vs. NC, #P < 0.05, ##P < 0.01 vs. IFITM3-LV. (c) IFITM3 partially localizes in LAMP1+ 
late endosome in HUVEC. Nucleus is counterstained with DAPI. IFITM3 (red) and LAMP1 (green) co-localization (yellow and orange dots) is evaluated by confocal 
microscopy.
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HTNV infection with a mechanism of cellular entry inhibition. 
Indeed, IFITM3 is localized to the late endosome in the host cells, 
which is a necessary structure for HTNV entry. In addition, we 
find that HTNV infection downregulated lncRNA NRIR 48  h 
post infection, which negatively regulates the transcription of 
IFITM3. Collectively, these results suggest that IFITM3, regu-
lated by NRIR, inhibits HTNV infection, and its SNP rs12252 
correlates with the disease severity and viral load in patients 
with HFRS.
The antiviral properties of IFITM proteins were identified in 
2009 in an RNAi screen for host factors that influence influenza 
virus replication (29). IFITM1, 2, and 3 have been demonstrated 
to possess antiviral activity in several studies. Everitt et  al. 
demonstrated that the severity of influenza virus infection was 
greatly increased in IFITM3-knockout mice compared with 
wild-type animals (15). Different IFITM members have also 
been confirmed to inhibit the cellular entry of multiple virus 
families (including filoviruses, rhabdoviruses, and flaviviruses) 
(7, 9–11, 30). For example, HIV-1 and HCV infection are inhib-
ited by IFITM1 (31–34). It is commonly believed that IFITMs 
restrict viral infection at the stage of cellular entry (12). Recent 
studies suggested that the cellular location of different IFITMs 
may influence the range of viruses restricted by each protein 
(5). IFITM1 prevents HCV entry because it colocalizes with 
CD81 on the cell membrane, interrupting the endocytosis of 
HCV particles (32), whereas IFITM3 confines influenza virus 
in acidified endosomal compartments (27). Notably, retrovirus 
subvirus particles (ISVPs), which do not require endosomal 
acidification for entry, are not inhibited by IFITM3 expression, 
suggesting that IFITM3 may function at the stage of endosomal 
entry (35). Studies utilizing cell–cell fusion assays have suggested 
that IFITM3 blocks the entry of enveloped virus by preventing 
the fusion of the viral membrane with a limiting membrane of 
the host cell, either the plasma membrane and/or the endosomal 
membranes. The results obtained using two-photon laser scan-
ning and fluorescence lifetime imaging (FLIM) suggest that 
IFITM proteins may reduce membrane fluidity and increase the 
spontaneous positive curvature in the outer leaflet of membranes 
(36). In the present study, we demonstrated that IFN-α2a (20 U/
ml) significantly inhibited HTNV infection, siRNA-mediated 
depletion of IFITM3 alone significantly mitigated the antiviral 
effect of IFN-α2a in both HUVEC and A549 cells, whereas deple-
tion of IFITM1 alone alleviated the antiviral effect of IFN-α2a in 
A549 cells. Overexpression of IFITM3 inhibited HTNV infection 
to HUVEC and A549 cells. IFITM1 overexpression was also effec-
tive in inhibition of HTNV in A549 cells. All these results suggest 
that IFITM3 is an important control factor under natural infec-
tion of HTNV. Our results also demonstrate that the effectiveness 
of IFITM3 is cell type-independent, which is in accordance with 
the results from similar viruses, such as RVFV (18). Binding 
and entry assays, conducted by controlling the temperature and 
pH, showed that IFITM3 did not significantly influence HTNV 
binding but inhibited HTNV entry into HUVEC and A549 cells. 
Indeed, IFITM3 partially localizes to the late endosome of the 
host cells, which is a necessary site for the HTNV entry. However, 
we failed in tracking the transportation of HTNV in infected cells 
possibly due to the lack of fluorescence-labeled virus. In addi-
tion, IFITM1 also suppressed HTNV infection in A549 cells. The 
mechanism underlying anti-HTNV effect of IFITM1 remains 
undetermined and deserves to be further explored.
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According to a recent study on the three-dimensional 
structure of IFITM3, there is a C-terminal transmembrane 
α-helix and a two-N-terminal intramembrane α-helices (shown 
in Figure  2A as black boxes) in IFITM3 (14). There are two 
splice variants that differ by the presence or absence of the first 
N-terminal 21 amino acids (deleted part, shown in Figure 2A 
as red dotted line). Several SNPs including 13 non-synonymous, 
13 synonymous, 1 in-frame stop, and 1 splice site acceptor-
altering have been reported in the translated IFITM3 sequence 
(15, 29). Among them, the rare SNP rs12252C allele of IFITM3 
truncates the protein as described above, leading to a reduced 
inhibition of influenza virus infection in A549 cells (15). We 
demonstrated that truncated IFITM3 protein also loses the abil-
ity to inhibit HTNV infection in vitro. In Northern European 
patients hospitalized with seasonal influenza or pandemic 
influenza A virus, increased homozygosity of the minor C 
allele of SNP rs12252 in IFITM3 was observed (37). In Chinese 
patients infected with influenza A (H1N1) virus, there was also 
an increased frequency of the C allele and CC genotype of SNP 
rs12252 (13). In the present study, we observed an increased 
frequency of the C allele and CC genotype of SNP rs12252 
in severely infected HFRS patients compared with healthy 
control and mildly affected patients. Patients carrying the CC 
genotype also had higher plasma viral loads compared with 
those with the CT/TT genotype. Given the impaired function 
of the IFITM3 protein produced by the C mutation, and the 
fact that enrichment of the rs12252 C allele in patients with 
severe disease and the higher viral load in patients with the CC 
genotype, this founding suggests that IFITM3 plays a pivotal 
role in the anti-HTNV response in vivo. We speculate that the 
much higher level of CC allele at healthy population of Han 
Chinese compared with Caucasians may place the Chinese at a 
higher risk for developing severe illness upon HTNV infection, 
which needs further investigation.
LncRNAs are a group of non-coding RNAs longer than 
200 nt that function as gene regulators, playing a role in regulat-
ing multiple cellular functions, including the innate immunity. 
For example, lncRNA NEAT1 is reported to be upregulated by 
influenza virus or PolyI:C stimulation, which promotes IL-8 
expression (38). lncRNA NRAV has been shown to negatively 
regulate the initial transcription of IFITM3 and Mx1 by affect-
ing the histone modification of these genes (25). lncRNA NRIR 
is a non-coding ISG, which has been reported to negatively 
regulate IFITM1 and Mx1 expression in HCV infection (20). 
Mir-130a was also reported as a regulator of IFITM1 (23). In 
this analysis, lncRNA NRIR was downregulated in HUVECs 
FigUre 7 | nrir negatively regulates the initial transcription of iFiTM3 and facilitates hTnV infection. (a) qPCR analysis of NRIR downregulation in 
HUVEC, but not in A549 cells, infected by mock control (Con) or HTNV, 48 h postinfection. (b) Overexpression of NRIR in HUVEC and A549 cells transfected by 
mock control (Con) or NRIR expressing plasmid, confirmed by qPCR. Values are mean ± SEM, n = 8, *P < 0.05, **P < 0.01 vs. Con. (D) Schematic dissection of 
IFITM3 pre-mRNA exons and intron for designing primers of qPCR analysis of IFITM3 pre-mRNA levels. (c,e) NRIR suppresses IFITM3 transcription in HUVEC and 
A549 cells and facilitated HTNV infection. Con: empty vector control, NRIR: NRIR overexpression group. Values are mean ± SEM, n = 8, *P < 0.05 vs. Con, 
**P < 0.01 vs. Con.
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NRIR for further study. Another lncRNA that can regulate 
IFITM3, i.e., NRAV (NR_038854), remained unchanged after 
HTNV infection (Figures S4A,B in Supplementary Material). 
Additionally, miR-130a, which potentially regulate IFITM3, 
was also unaltered after HTNV infection (Figures S4C,D in 
Supplementary Material).
In conclusion, this study revealed a critical role for IFITM3 
in HTNV infection. We demonstrated, for the first time to our 
knowledge, that IFITM3 is a newly identified anti-HTNV ISG; 
its expression is negatively regulated by NRIR; and its antiviral 
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anti-HTNV function. These results provide new insights into the 
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infection, which is the basis for identifying new targets to develop 
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